Get the Stockscreener App
9.92
0.70%
-0.07
After Hours:
9.92
Syndax Pharmaceuticals Inc stock is traded at $9.92, with a volume of 1.99M.
It is down -0.70% in the last 24 hours and up +5.93% over the past month.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
See More
Previous Close:
$9.99
Open:
$9.77
24h Volume:
1.99M
Relative Volume:
0.90
Market Cap:
$853.59M
Revenue:
$139.71M
Net Income/Loss:
$-209.36M
P/E Ratio:
-3.3514
EPS:
-2.96
Net Cash Flow:
$-160.60M
1W Performance:
-0.70%
1M Performance:
+5.93%
6M Performance:
-29.99%
1Y Performance:
-56.30%
1-Day Range:
$9.565
$10.04
1-Week Range:
$9.42
$10.75
52-Week Range:
$8.58
$22.98
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Name
Syndax Pharmaceuticals Inc
Sector
Industry
Phone
781-419-1400
Address
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
9.92 | 859.61M | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Jun-28-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Oct-25-23 | Initiated | BofA Securities | Buy |
| Oct-11-23 | Initiated | Goldman | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-11-23 | Initiated | Guggenheim | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jan-03-23 | Initiated | JP Morgan | Overweight |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Apr-11-22 | Initiated | H.C. Wainwright | Buy |
| Feb-15-22 | Initiated | Goldman | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-25-21 | Initiated | Citigroup | Buy |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| May-22-20 | Upgrade | Citigroup | Neutral → Buy |
| May-22-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-18-20 | Downgrade | Citigroup | Buy → Neutral |
| May-11-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
| Jan-04-19 | Initiated | Robert W. Baird | Outperform |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Mar-16-17 | Initiated | FBR & Co. | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Oct-07-16 | Initiated | Guggenheim | Buy |
| Mar-28-16 | Initiated | Citigroup | Buy |
| Mar-28-16 | Initiated | JMP Securities | Mkt Outperform |
| Mar-28-16 | Initiated | Morgan Stanley | Overweight |
View All
Syndax Pharmaceuticals Inc Stock (SNDX) Latest News
What is Syndax Pharmaceuticals Inc. company’s growth strategyMarket Forecast Opportunities Backed By Experts - jammulinksnews.com
Syndax Pharmaceuticals Inc to Host Earnings Call - ACCESS Newswire
Syndax Pharmaceuticals (SNDX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 6.2%Still a Buy? - MarketBeat
Screener Results Flag Syndax Pharmaceuticals Inc. as OversoldConservative Entry for High Return Setup Backed - beatles.ru
All You Need to Know About Syndax (SNDX) Rating Upgrade to Buy - Yahoo Finance
Wall Street Analysts Predict a 237.83% Upside in Syndax (SNDX): Here's What You Should Know - Yahoo Finance
Bollinger Bands Show Potential Breakout in Syndax Pharmaceuticals Inc.Smart Trade Plans With Risk Protection Explained - metal.it
Published on: 2025-07-29 05:21:51 - metal.it
Recovery Setup Building in Syndax Pharmaceuticals Inc. Experts SayReal-Time Market Sentiment Tracking Gains Momentum - metal.it
What are the latest earnings results for Syndax Pharmaceuticals Inc.Beginner Investor Tips With Low Risk - jammulinksnews.com
Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025 - GlobeNewswire
What is the dividend policy of Syndax Pharmaceuticals Inc. stockInvest confidently with professional market insights - jammulinksnews.com
Syndax Pharmaceuticals: A Dual-Driven Catalyst for Long-Term Shareholder Value in 2025 - AInvest
Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025 | SNDX Stock News - GuruFocus
Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025 - GlobeNewswire Inc.
How does Syndax Pharmaceuticals Inc. generate profit in a changing economyMaximize your portfolio’s growth with expert tips - jammulinksnews.com
Does Syndax Pharmaceuticals Inc. stock perform well during market downturnsCapital growth strategies that work - jammulinksnews.com
Syndax Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SayHigh Potential Safe Trades - metal.it
Is Syndax Pharmaceuticals Inc. a growth stock or a value stockAmplify your gains with low-risk picks - jammulinksnews.com
How volatile is Syndax Pharmaceuticals Inc. stock compared to the marketStay ahead with daily expert stock picks - jammulinksnews.com
How strong is Syndax Pharmaceuticals Inc. company’s balance sheetRecord-breaking gains - jammulinksnews.com
How high can Syndax Pharmaceuticals Inc. stock price go in 2025Free Best Performing Stock Alerts - metal.it
Is Syndax Pharmaceuticals Inc. a good long term investmentRecord-setting profit potential - PrintWeekIndia
What analysts say about Syndax Pharmaceuticals Inc. stockRapid market gains - PrintWeekIndia
Should I buy Syndax Pharmaceuticals Inc. stock before earningsGame-changing capital returns - jammulinksnews.com
What drives Syndax Pharmaceuticals Inc. stock priceDynamic capital growth - PrintWeekIndia
Syndax Pharmaceuticals’ Promising AML Study: A Closer Look at SNDX-5613 - TipRanks
Syndax Pharmaceuticals Inc. Stock Analysis and ForecastDouble-digit growth - Autocar Professional
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Keith A. Goldan Sells 1,296 Shares - MarketBeat
Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group Acquires New Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CEO Sells $69,990.86 in Stock - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Teacher Retirement System of Texas - Defense World
Analysts Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) PT at $34.10 - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Cut to $35.00 by Analysts at UBS Group - MarketBeat
Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):